These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34768267)

  • 1. Subtypes of Major Depressive Disorder Based on Pharmacological Responsiveness.
    Preskorn SH
    J Psychiatr Pract; 2021 Nov; 27(6):448-452. PubMed ID: 34768267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent.
    Preskorn S; Macaluso M; Mehra DO; Zammit G; Moskal JR; Burch RM;
    J Psychiatr Pract; 2015 Mar; 21(2):140-9. PubMed ID: 25782764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamatergic NMDA Receptor as Therapeutic Target for Depression.
    Réus GZ; Abelaira HM; Tuon T; Titus SE; Ignácio ZM; Rodrigues AL; Quevedo J
    Adv Protein Chem Struct Biol; 2016; 103():169-202. PubMed ID: 26920690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of NMDA receptors in the pathophysiology and treatment of mood disorders.
    Ghasemi M; Phillips C; Trillo L; De Miguel Z; Das D; Salehi A
    Neurosci Biobehav Rev; 2014 Nov; 47():336-58. PubMed ID: 25218759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sigma-1 receptor: A potential target for the development of antidepressants.
    Wang YM; Xia CY; Jia HM; He J; Lian WW; Yan Y; Wang WP; Zhang WK; Xu JK
    Neurochem Int; 2022 Oct; 159():105390. PubMed ID: 35810915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of lingual gyrus volume on antidepressant response and neurocognitive functions in Major Depressive Disorder: a voxel-based morphometry study.
    Jung J; Kang J; Won E; Nam K; Lee MS; Tae WS; Ham BJ
    J Affect Disord; 2014 Dec; 169():179-87. PubMed ID: 25200096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.
    Niciu MJ; Ionescu DF; Richards EM; Zarate CA
    J Neural Transm (Vienna); 2014 Aug; 121(8):907-24. PubMed ID: 24318540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
    Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of response to antidepressants in major depressive disorder: Drug resistance or worsening of depression are associated with a bipolar diathesis.
    Perugi G; Pacchiarotti I; Mainardi C; Verdolini N; Menculini G; Barbuti M; Angst J; Azorin JM; Bowden CL; Mosolov S; Young AH; Vieta E;
    Eur Neuropsychopharmacol; 2019 Jul; 29(7):825-834. PubMed ID: 31227264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of a Single Nucleotide Polymorphism in SIGMAR1 on Depressive Symptoms in Major Depressive Disorder and Bipolar Disorder.
    Mandelli L; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Pae CU; Serretti A
    Adv Ther; 2017 Mar; 34(3):713-724. PubMed ID: 28144920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Development in Psychiatry: The Long and Winding Road from Chance Discovery to Rational Development.
    Preskorn SH
    Handb Exp Pharmacol; 2019; 250():307-324. PubMed ID: 30570691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of Exploring N-Methyl-D-Aspartate (NMDA) as a Future Perspective Target in Depression.
    Bhatia NY; Ved HS; Kale PP; Doshi GM
    CNS Neurol Disord Drug Targets; 2022; 21(10):1004-1016. PubMed ID: 35352638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ketamine and other potential glutamate antidepressants.
    Dutta A; McKie S; Deakin JFW
    Psychiatry Res; 2015 Jan; 225(1-2):1-13. PubMed ID: 25467702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A brief history of the development of antidepressant drugs: from monoamines to glutamate.
    Hillhouse TM; Porter JH
    Exp Clin Psychopharmacol; 2015 Feb; 23(1):1-21. PubMed ID: 25643025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging drugs for major depressive disorder.
    Connolly KR; Thase ME
    Expert Opin Emerg Drugs; 2012 Mar; 17(1):105-26. PubMed ID: 22339643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants.
    Chen T; Cheng L; Ma J; Yuan J; Pi C; Xiong L; Chen J; Liu H; Tang J; Zhong Y; Zhang X; Liu Z; Zuo Y; Shen H; Wei Y; Zhao L
    Pharmacol Res; 2023 Aug; 194():106837. PubMed ID: 37379962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized medicine in major depressive disorder -- opportunities and pitfalls.
    Miller DB; O'Callaghan JP
    Metabolism; 2013 Jan; 62 Suppl 1(0 1):S34-9. PubMed ID: 23021040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of glutamate on the action of antidepressants.
    Hashimoto K
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1558-68. PubMed ID: 20600468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutamate-based antidepressants: 20 years on.
    Skolnick P; Popik P; Trullas R
    Trends Pharmacol Sci; 2009 Nov; 30(11):563-9. PubMed ID: 19837463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoamine neurocircuitry in depression and strategies for new treatments.
    Hamon M; Blier P
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.